Telomir Pharmaceuticals Inc TELO Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$1.05 down $0.04, 3.67% on Oct 14
Last price · Previous close $1.09
- Market cap
- At the last price
- P/E ratio
- On last 12 months’ EPS
- Diluted EPS
- Last 12 months
- Dividend yield
- Last 12 months
Price chart
$1.05down $0.04, 3.67%Wed, Oct 14 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$1.09Oct 13
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Valuation
Financials
Dividends
About Telomir Pharmaceuticals Inc
Telomir Pharmaceuticals, Inc. is a pre-clinical stage pharmaceutical company seeking to lead development in several areas, including age-reversal science. Telomir is focused on the development of Telomir-1, a novel small molecule metal ion regulator designed to lengthen the DNA's protective telomere caps, which are crucial in the aging process. Telomir's goal is to explore the potential of Telomir-1, starting with ongoing research in animals and then in humans. Telomeres are the protective end caps of a chromosome made up of DNA sequences and proteins. As humans age, telomeres shorten, with metal reactivity accelerating the process, which presents humans and pet animals with an increased chance of contracting a number of degenerative and age-related diseases. Telomir's goal is to develop and gain regulatory approval for Telomir-1, proposed to be dosed orally, with the broader aim of promoting longevity and enhancing overall quality of life. Telomir-1 is in preclinical development and has not yet been tested in humans. There is no assurance that Telomir-1 will proceed through development or will ultimately receive FDA approval for marketing.
- Sector
- Industry
- Headquarters
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
TELO news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
TELO stock FAQ
What is TELO stock’s price today?
Telomir Pharmaceuticals (TELO) traded at $1.05 as of , down $0.04 (3.67%) from the previous close of $1.09.
What exchange does TELO trade on?
Telomir Pharmaceuticals trades on the Nasdaq under the ticker symbol TELO. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.